COMPANY PROFILE

Atritech

Explore full profile

WATCHMAN™ Left Atrial Appendage Closure Device | Warfarin Therapy Alternative | Boston Scientific

Plymouth, United StatesFounded 2000Biotech & Life Sciences

Valuation $250–500M Last recorded · 2011

Total funding $50–100M Disclosed equity funding

At a glance

Status: Acquired
Founded: 2000
Headquarters: Plymouth, United States
Open positions: None listed
Dealroom signal: 24.3/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Horizon Europe, DT and LS, science-based
Technology: Hardware
Business model: Manufacturing
Client focus: b2c
Investment activity: 1 company, latest Jan 2013
Capital deployed: $0
Preferred round: GRANT

Founder mafia, market maps, research and news connected to this company by Dealroom

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jan 2011	$375M	$375M	Boston Scientific	—
LATE VCOther financing	Mar 2009	$30M	$120M	Prism Venture Management · Split Rock Partners · Vector Media Group	—

Atritech website traffic

Latest recorded traffic for Atritech is 660K monthly website visits, up 10% over the last three months.

Latest monthly visits660K 3-month web change+10%

Monthly website visitsNov 2018–Feb 2026

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational	11	$3.4M	$7M
GAGLX AnalytixBringing personalized medicine to your health care	Copenhagen, Denmark	Operational
STStayble TherapeuticsNew treatment for chronic back pain	Göteborgs Stad, Sweden	Operational
MAMabylonAntibody-based therapeutics for allergies, inflammation, and neurological disorders using human B-cell screening	Zurich, Switzerland	Operational
IMiCellate MedicalDevelops products in the areas of cancer diagnosis, based on detection and analyses of circulating tumour cells (CTC), circulating tumour DNA (ctDNA) and germline DNA	Solna kommun, Sweden	Operational
TITiGenixLocal treatments for damaged and osteoarthritic joints	Leuven, Belgium	Acquired
CACalcivisBiotechnology-driven imaging system for early detection and prevention of tooth demineralization	Edinburgh, United Kingdom	Operational
CSClair ScientificAffordable automated microscopes delivering top-tier speed and optical performance	Herlev, Denmark	Operational